Fibrosis and disease progression in hepatitis C. - sprookjes - yvandenbroek - TriplyDB

Fibrosis and disease progression in hepatitis C.

Fibrosis and disease progression in hepatitis C.

http://www.wikidata.org/entity/Q34984040

about

Identification and comparative analysis of hepatitis C virus-host cell protein interactions Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom Magnetic Resonance Elastography and Other Magnetic Resonance Imaging Techniques in Chronic Liver Disease: Current Status and Future Directions.Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals Steatosis and hepatitis C Magnetic resonance elastography of liver: technique, analysis, and clinical applications.Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C Gene expression and hepatitis C virus infection Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.Mechanisms and significance of liver steatosis in hepatitis C virus infection Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study.Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C.Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.Detection of novel biomarkers of liver cirrhosis by proteomic analysis.Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.Managing HCV infection in pediatric age group: suggested recommendations.Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study.LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection.Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.Fibrosis progression in chronic hepatitis C virus infection.Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy.Review article: the evolving role of liver biopsy.Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray The impact of host factors on management of hepatitis C virus.

P2860

Q24338554-0179F51F-30E2-40E5-8352-1E2E2E070982 Q25256731-EC9CB02C-5C47-4CA1-81DA-60918064B896 Q26738871-82623B7C-C3E1-4353-8A16-E96CB8640CBD Q26781984-0986550B-1F77-43ED-ABC2-170C6DAE07D7 Q26782033-4A7393B4-CF97-495E-8678-A8CFA7C9F56B Q26798101-30383FCE-D392-4669-B9A3-87EF7F1281FE Q27027849-2D442446-F63D-4E2F-8C77-094D6F716C1B Q27477966-CAB9DC13-C9AE-4647-8131-60F293383A18 Q27478329-5B1774B3-B7C8-4C5E-9739-D99DA447A7E6 Q27482028-8EFABD3C-044C-4BEC-84EB-B6F3B33A9DD8 Q27488345-28BF62F8-F205-4A6D-B3B2-4C7CDD98F9F0 Q27490544-EB69EA37-0293-412A-9D20-122D5877C721 Q30375738-C2DC6344-A6F5-43A8-9D8D-D874B5C33498 Q30476922-FFB261BF-632D-4654-BB7E-562440D941CB Q33862153-B4C5C6BD-CE98-48F5-888A-980E45804F63 Q33866272-520D345B-2076-4638-9ABB-330291F6DF6A Q33866459-D95ADAC4-DD39-4734-B05C-F6E578E837D1 Q33867064-DDAFE02A-88D7-4FA4-8CC0-A53B1B0AEFC9 Q33887760-61F1DFEF-69B4-4801-BC50-5A0BE511677F Q33898567-C3991997-6E85-472F-9936-2445A1013F2A Q33938574-68267034-2565-4728-9620-783F74E4FA72 Q33954802-753EACA4-46BA-4326-A447-196AF81B4513 Q34064042-287B06F9-8469-470B-A992-D9C167610AB3 Q34279897-44F531DC-251A-454A-8FA3-103D0B35C20B Q34411942-A4609DBE-C5FD-43E0-8C34-6FFB0593763D Q34450720-AA20DEEE-6C48-4593-9C2C-E3DB406708D4 Q34769512-8B2236AF-B157-472C-A87C-39B872C32616 Q35010511-760DCD83-3987-4FE5-AAC0-61EB599F38F3 Q35053127-299FF90B-8B38-444E-A361-955B32FEC60D Q35103291-34D07669-3996-491E-A446-CFC728602068 Q35105799-16BA6CBC-BB00-4681-8C19-18087437D04C Q35199268-D6C7EDCE-091A-4881-917A-1F5DA22B4E53 Q35284740-9D0E5D93-1C36-4F24-B7D8-DB9C63E396BF Q35397221-58CE9122-0492-4BFF-94E9-0286228AFDC1 Q35666213-327161EC-3392-4216-9FA3-7BA8E8DC8922 Q35761351-CB4D9ABA-2EAB-4925-A5B8-5494AD6A18D2 Q35845834-6404922D-CC16-41D4-B483-DF5D277A23D0 Q35872121-07FE2361-E024-46ED-9ACE-AAF6A1A287CB Q35945962-D559B287-C40A-4227-AE1B-7A18865C2B68 Q35990066-3B2987A8-FDC9-410E-855E-B7DABD814A40

P2860

Fibrosis and disease progression in hepatitis C.

http://www.wikidata.org/entity/Q34984040

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Fibrosis and disease progression in hepatitis C.

@ast

Fibrosis and disease progression in hepatitis C.

@en

Fibrosis and disease progression in hepatitis C.

@nl

type

label

Fibrosis and disease progression in hepatitis C.

@ast

Fibrosis and disease progression in hepatitis C.

@en

Fibrosis and disease progression in hepatitis C.

@nl

prefLabel

Fibrosis and disease progression in hepatitis C.

@ast

Fibrosis and disease progression in hepatitis C.

@en

Fibrosis and disease progression in hepatitis C.

@nl

P1433

Q34984040-5EAB9D77-7823-4967-8619-8BE261F45E2B

P1476

Q34984040-21464E3B-67D0-4C27-A531-014948D55CCF

P2093

Q34984040-046C19B4-AC4D-4C0A-AB24-3A41D4DDF818

Q34984040-5EFC29A7-4C6E-44E0-90D0-CB89099D5B32

Q34984040-8F0E9698-1581-4C1C-9562-2EA85A3F0A51

P2860

Q34984040-0B8EF09B-1226-4A9A-89CE-00CD24CF8B6C

Q34984040-2039B0CC-66AF-4F88-941D-705E083112FC

Q34984040-242EA0E3-DBBB-4E55-A292-88CEFB668081

Q34984040-3143900E-08A6-487D-892A-30B4548BA218

Q34984040-39EDA11B-9EFE-47A3-8C51-3240C71AF7AB

Q34984040-3A027963-799A-45E6-BAB1-7F43837C8B92

Q34984040-4039989F-1F4C-420E-A592-F6A95BD52F34

Q34984040-40AE95C9-6456-4ECD-B6FA-5A254B0299BC

Q34984040-44C4E66D-3093-41A5-BCE5-0E5BCDF277FD

Q34984040-4B56F48F-CE9D-49FD-81A3-F0CDAF3360AC

P304

Q34984040-4584F98A-ABC7-425B-BE81-1D0DE2A1166D

P31

Q34984040-F1152A45-BEC0-4C22-BA0E-2CC1E4E17847

P356

Q34984040-D3BA8EDA-9827-4DB2-A5DF-05D5F8ADBDE9

P407

Q34984040-500119BB-AB1B-4B7F-B512-86F5703C51DE

P433

Q34984040-68B96219-351F-45D3-8790-9D2F4B439109

P478

Q34984040-0CEF005C-A7CF-41CC-BBE9-052C0AC9C132

P577

Q34984040-AA7D4EE0-4AD6-4385-80C7-259FD61C6A52

P5875

Q34984040-9AC248C6-562F-40BE-BD9F-A0CF88906DA8

P698

Q34984040-9D423AC6-3ABB-4166-A2D8-8A59B5C63AE1

P356

JHEP.2002.36993

P1433

P1476

Fibrosis and disease progression in hepatitis C.

@en

P2093

Nathalie Boyer

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Tarik Asselah

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

Histological grading and staging of chronic hepatitis

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

Hepatitis C: the clinical spectrum of the disease.

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.

Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

P304

S47-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.36993

http://www.w3.org/2001/XMLSchema#string

P407

P433

5 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11056233

http://www.w3.org/2001/XMLSchema#string

P698

12407576

http://www.w3.org/2001/XMLSchema#string